Drug (ID: DG00208) and It's Reported Resistant Information
Name
Everolimus
Synonyms
Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress
    Click to Show/Hide
Indication
In total 1 Indication(s)
Renal cell carcinoma [ICD-11: 2C90]
Approved
[1]
Structure
Drug Resistance Disease(s)
Disease(s) with Clinically Reported Resistance for This Drug (5 diseases)
Breast cancer [ICD-11: 2C60]
[2]
Kidney cancer [ICD-11: 2C90]
[3]
Pancreatic cancer [ICD-11: 2C10]
[4]
Prostate hyperplasia [ICD-11: GA90]
[5]
Thyroid cancer [ICD-11: 2D10]
[6]
Target Serine/threonine-protein kinase mTOR (mTOR) MTOR_HUMAN [1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula
C53H83NO14
IsoSMILES
C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC
InChI
1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
InChIKey
HKVAMNSJSFKALM-GKUWKFKPSA-N
PubChem CID
6442177
ChEBI ID
CHEBI:68478
TTD Drug ID
D0K3QS
VARIDT ID
DR00224
INTEDE ID
DR0674
DrugBank ID
DB01590
Type(s) of Resistant Mechanism of This Drug
  ADTT: Aberration of the Drug's Therapeutic Target
  EADR: Epigenetic Alteration of DNA, RNA or Protein
  RTDM: Regulation by the Disease Microenvironment
  UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Click to Show/Hide the Resistance Disease of This Class
Pancreatic cancer [ICD-11: 2C10]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Unusual Activation of Pro-survival Pathway (UAPP) Click to Show/Hide
Key Molecule: Eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1) [4]
Molecule Alteration Expression
Up-regulation
Resistant Disease Pancreatic neuroendocrine tumor [ICD-11: 2C10.1]
Experimental Note Identified from the Human Clinical Data
Cell Pathway Regulation PI3K/AKT/mTOR signaling pathway Activation hsa04151
CXCR4-CXCL12-CXCR7 signaling pathway Activation hsa04061
In Vitro Model A498 cells Kidney Homo sapiens (Human) CVCL_1056
SN12C cells Kidney Homo sapiens (Human) CVCL_1705
Experiment for
Molecule Alteration
Western blotting assay
Mechanism Description When the CXCR4-CXCL12-CXCR7 pathway is activated through CXCL12 in human renal cancer cells were, SN12C and A498, CXCL12 induced the mTOR targets p-P70S6K and p-4EBP1.The combination therapy of mTOR inhibitors with the CXCR4-CXCL12-CXCR7 axis inhibitors in renal cancer tumors could overcome the Everolimus resistance.
Key Molecule: Ribosomal protein S6 kinase beta-1 (RPS6KB1) [4]
Molecule Alteration Expression
Up-regulation
Resistant Disease Pancreatic neuroendocrine tumor [ICD-11: 2C10.1]
Experimental Note Identified from the Human Clinical Data
Cell Pathway Regulation PI3K/AKT/mTOR signaling pathway Activation hsa04151
CXCR4-CXCL12-CXCR7 signaling pathway Activation hsa04061
In Vitro Model A498 cells Kidney Homo sapiens (Human) CVCL_1056
SN12C cells Kidney Homo sapiens (Human) CVCL_1705
Experiment for
Molecule Alteration
Western blotting assay
Mechanism Description When the CXCR4-CXCL12-CXCR7 pathway is activated through CXCL12 in human renal cancer cells were, SN12C and A498, CXCL12 induced the mTOR targets p-P70S6K and p-4EBP1.The combination therapy of mTOR inhibitors with the CXCR4-CXCL12-CXCR7 axis inhibitors in renal cancer tumors could overcome the Everolimus resistance.
Breast cancer [ICD-11: 2C60]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Unusual Activation of Pro-survival Pathway (UAPP) Click to Show/Hide
Key Molecule: Mth938 domain-containing protein (AAMDC) [2]
Molecule Alteration Expression
Up-regulation
Resistant Disease Breast cancer [ICD-11: 2C60.3]
Experimental Note Identified from the Human Clinical Data
Cell Pathway Regulation Cell apoptosis Inhibition hsa04210
Cell migration Activation hsa04670
Cell proliferation Activation hsa05200
PI3K/AKT/mTOR signaling pathway Activation hsa04151
In Vitro Model MCF-7 cells Breast Homo sapiens (Human) CVCL_0031
SkBR3 cells Breast Homo sapiens (Human) CVCL_0033
MDA-MB-231 cells Breast Homo sapiens (Human) CVCL_0062
HEK293T cells Kidney Homo sapiens (Human) CVCL_0063
T47D cells Breast Homo sapiens (Human) CVCL_0553
ZR75-1 cells Breast Homo sapiens (Human) CVCL_0588
BT549 cells Breast Homo sapiens (Human) CVCL_1092
MCF-12A cells Breast Homo sapiens (Human) CVCL_3744
SUM159 cells Breast Homo sapiens (Human) CVCL_5423
SUM44PE cells Breast Homo sapiens (Human) CVCL_3424
SUM52PE cells Breast Homo sapiens (Human) CVCL_3425
In Vivo Model BALB/cJ Foxn1/Arc nude mice xenografts model Mus musculus
Experiment for
Molecule Alteration
Western blotting analysis
Experiment for
Drug Resistance
CellTiter-Glo 2.0 luminescence assay protocol assay
Mechanism Description High AAMDC expression is associated with sensitization to dactolisib and everolimus, and these PI3k-mTOR inhibitors exhibit synergistic interactions with anti-estrogens in IntClust2 models. Ectopic AAMDC expression is sufficient to activate AkT signaling, resulting in estrogen-independent tumor growth. Thus, AAMDC-overexpressing tumors may be sensitive to PI3k-mTORC1 blockers in combination with anti-estrogens.
Prostate cancer [ICD-11: 2C82]
Click to Show/Hide
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Epigenetic Alteration of DNA, RNA or Protein (EADR) Click to Show/Hide
Key Molecule: Growth arrest specific 5 (GAS5) [1]
Molecule Alteration Expression
Up-regulation
Sensitive Disease Prostate cancer [ICD-11: 2C82.0]
Experimental Note Revealed Based on the Cell Line Data
Cell Pathway Regulation Cell proliferation Inhibition hsa05200
In Vitro Model DU-145 cells Prostate Homo sapiens (Human) CVCL_0105
LNCaP cells Prostate Homo sapiens (Human) CVCL_0395
PC3 cells Prostate Homo sapiens (Human) CVCL_0035
22RV1 cells Prostate Homo sapiens (Human) CVCL_1045
PNT2C2 cells Prostate Homo sapiens (Human) CVCL_4889
Experiment for
Molecule Alteration
qRT-PCR
Experiment for
Drug Resistance
GAS5 assay; MTS assay
Mechanism Description First generation mTORC1, combined mTORC1/mTORC2 and dual PI3k/mTOR inhibitors all increased cellular GAS5 levels and inhibited culture growth in androgen-dependent (LNCaP) and androgen-sensitive (22Rv1) cell lines, but not in androgen-independent (PC-3 and DU 145) cell lines. The latter exhibited low endogenous GAS5 expression, and GAS5 silencing in LNCaP and 22Rv1 cells decreased the sensitivity to mTOR inhibitors, whereas transfection of GAS5 LncRNA sensitized PC-3 and DU 145 cells to these agents.
Kidney cancer [ICD-11: 2C90]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Regulation by the Disease Microenvironment (RTDM) Click to Show/Hide
Key Molecule: hsa-mir-92a [3]
Molecule Alteration Expression
Up-regulation
Resistant Disease Kidney cancer [ICD-11: 2C90.1]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Caki-1 cells Kidney Homo sapiens (Human) CVCL_0234
786-O cells Kidney Homo sapiens (Human) CVCL_1051
ACHN cells Pleural effusion Homo sapiens (Human) CVCL_1067
A498 cells Kidney Homo sapiens (Human) CVCL_1056
Experiment for
Molecule Alteration
qRT-PCR
Experiment for
Drug Resistance
CCK8 assay
Mechanism Description NC886 also promotes renal cancer cell drug-resistance to Sunitinib or Everolimus by promoting EMT through Rock2 phosphorylation-mediated nuclear translocation of beta-catenin.
Thyroid cancer [ICD-11: 2D10]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Aberration of the Drug's Therapeutic Target (ADTT) Click to Show/Hide
Key Molecule: Serine/threonine-protein kinase mTOR (mTOR) [6]
Molecule Alteration Missense mutation
p.F2108L
Resistant Disease Thyroid carcinoma [ICD-11: 2D10.4]
Experimental Note Identified from the Human Clinical Data
Cell Pathway Regulation mTOR signaling pathway Activation hsa04150
Experiment for
Molecule Alteration
Whole-exome sequencing assay; Whole-genome sequencing assay
Experiment for
Drug Resistance
Computerized tomography assay
Mechanism Description On the basis of these findings, we hypothesized that mTORF2108L causes resistance to allosteric mTOR inhibition by preventing the binding of the drug to the protein.
ICD-16: Genitourinary system diseases
Click to Show/Hide the Resistance Disease of This Class
Prostate hyperplasia [ICD-11: GA90]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Unusual Activation of Pro-survival Pathway (UAPP) Click to Show/Hide
Key Molecule: NPR2 like, GATOR1 complex subunit (NPRL2) [5]
Molecule Alteration Expression
Up-regulation
Resistant Disease Prostate hyperplasia [ICD-11: GA90.0]
Experimental Note Identified from the Human Clinical Data
Cell Pathway Regulation mTOR signaling pathway Inhibition hsa04150
In Vitro Model PC3 cells Prostate Homo sapiens (Human) CVCL_0035
RWPE-1 cells Prostate Homo sapiens (Human) CVCL_3791
PCa LNCaP cells Prostate Homo sapiens (Human) CVCL_D575
In Vivo Model Balb/c athymic nude mouse xenograft model Mus musculus
Experiment for
Molecule Alteration
Western blotting assay
Experiment for
Drug Resistance
CCK8 assay
Mechanism Description NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.NPRL2-silencing increased the activity of mTOR signaling, and the autophagy attenuation induced by NPRL2-silencing in EVS-treated CRPC cells was associated with the increase of apoptosis.
References
Ref 1 Reciprocal regulation of GAS5 lncRNA levels and mTOR inhibitor action in prostate cancer cells. Prostate. 2015 May;75(7):693-705. doi: 10.1002/pros.22952. Epub 2015 Feb 3.
Ref 2 The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer. Nat Commun. 2021 Mar 26;12(1):1920. doi: 10.1038/s41467-021-22101-7.
Ref 3 Nc886 promotes renal cancer cell drug-resistance by enhancing EMT through Rock2 phosphorylation-mediated Beta-catenin nuclear translocation .Cell Cycle. 2022 Feb;21(4):340-351. doi: 10.1080/15384101.2021.2020431. Epub 2022 Jan 2. 10.1080/15384101.2021.2020431
Ref 4 Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it .Int J Surg. 2015 Sep;21 Suppl 1:S89-94. doi: 10.1016/j.ijsu.2015.06.064. Epub 2015 Jun 27. 10.1016/j.ijsu.2015.06.064
Ref 5 NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer .Prostate. 2019 Jan;79(1):44-53. doi: 10.1002/pros.23709. Epub 2018 Sep 3. 10.1002/pros.23709
Ref 6 Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014 Oct 9;371(15):1426-33. doi: 10.1056/NEJMoa1403352.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.